Table 1.
Clinical background information of the Met-pa participating in this study
| Patient characteristics | |
|---|---|
| Total, N | 52 |
| Age (years), mean (range) | 64 (40–83) |
| Gender, N (%) | |
| Female | 26 (50%) |
| Male | 26 (50%) |
| Type of cancer, N (%) | |
| Colon and rectum | 16 (31%) |
| Breast | 6 (12%) |
| Lung | 7 (13%) |
| Pancreatic | 6 (12%) |
| Gastric | 3 (6%) |
| Esophageal | 2 (4%) |
| Cervical, endometrial, ovarian | 4 (8%) |
| Renal | 3 (6%) |
| Prostate | 4 (8%) |
| Metastasis location, N (%) | |
| Lung | 16 (21%) |
| Bone | 14 (18%) |
| Abdomen | 5 (7%) |
| Liver | 23 (30%) |
| Pancreas | 2 (3%) |
| Brain | 4 (5%) |
| Lymph nodes | 3 (4%) |
| Pericardial effusion | 2 (3%) |
| Omentum | 2 (3%) |
| Cervical/uterus | 4 (5%) |
| Scrotum | 1 (1%) |
| Chemotherapy, N (%) | |
| 5-Fluorouracil, Irinotecan, Oxaliplatin | 10 (19%) |
| Taxanes (Taxol, Paclitaxel, Docetaxel) | 5 (10%) |
| Alkylating agents (Carboplatin, Irinotecan, Cisplatin, Etopisode) | 4 (8%) |
| Antimetabolites (Trabectedin, Capecitabine, Trifluridine, Pemetrexed) | 6 (12%) |
| Inhibitor (Copanisilib, Pembrolizumab, Topotecan, Arbiraterone) | 27 (52%) |